Nu-Med Plus (NUMD) Cost of Revenue (2023 - 2024)

Nu-Med Plus' (NUMD) quarterly Cost of Revenue came in at $300.0 in Q1 2024, down 90.0% quarter-over-quarter from $3000.0 in Q4 2023.

Nu-Med Plus (NUMD) Cost of Revenue (2023 - 2024) Analysis & Trends

Nu-Med Plus has disclosed Cost of Revenue across 2 years of filings, most recently posting $300.0 for Q1 2024.

Cost of Revenue for Q1 2024 came in at $300.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $300.0 (changed N/A YoY), and the FY2025 annual result was $58.0, down 80.67% from the prior year.
Cost of Revenue came in at $300.0 for Q1 2024 at Nu-Med Plus, down from $3000.0 in the prior quarter.
In the past five years, Cost of Revenue ranged from a high of $3300.0 in Q3 2023 to a low of $300.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	4.89 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	2.21 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	3.26 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	1.59 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	362.60 Mn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	481.00 Mn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	2.51 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	441.60 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	891.20 Mn
10	Nu-Med Plus	-	-	-	-

Download Data